H7N9 vaccine may prove too little, too late

The H7N9 vaccine may arrive too late and with too little manufacturing capacity to really help, a New Scientist feature warns. Delays in ramping up production and the need to use large doses in vaccines for H7 viruses could hamper immunization efforts. Feature

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.